Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 1989;80:1240-1246

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rossen, J. D.
Right arrow Articles by Winniford, M. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rossen, J. D.
Right arrow Articles by Winniford, M. D.

Circulation, Vol 80, 1240-1246, Copyright © 1989 by American Heart Association


ARTICLES

The effect of diltiazem on coronary flow reserve in humans

JD Rossen, I Simonetti, ML Marcus, P Braun and MD Winniford
Cardiovascular Division, University of Iowa College of Medicine, Iowa City.

Calcium channel antagonists have been shown to blunt maximal coronary flow after brief coronary occlusion and during pharmacologic coronary dilation in animals. This property, if present in humans, would result in a reduction in coronary flow reserve in the absence of intrinsic abnormalities of the coronary circulation. A reduction of maximal vasodilator capacity by calcium channel antagonists could also constitute an important anti-ischemic mechanism of action of these agents. To evaluate the effect of calcium channel antagonists on coronary flow reserve in awake humans, we measured coronary flow reserve using the coronary Doppler catheter and intracoronary papaverine at baseline and after diltiazem administered by intravenous (125 or 250 micrograms/kg bolus, 5 micrograms/kg/min infusion, n = 8) or intracoronary (150-600 micrograms bolus, n = 10) routes. Intravenous diltiazem reduced heart rate from 77 +/- 18 to 72 +/- 17 beats/min (mean +/- SD, p less than 0.005) and reduced mean arterial pressure from 96 +/- 11 to 86 +/- 15 mm Hg (p less than 0.005). Intravenous diltiazem resulted in a small decrease in coronary flow reserve (peak- to-resting flow velocity ratio) from 3.9 +/- 1.2 to 3.6 +/- 1.1 (p less than 0.01). After intracoronary diltiazem, mean arterial pressure was unchanged (control 99 +/- 12 mm Hg, diltiazem 97 +/- 13 mm Hg), and heart rate was maintained constant by atrial pacing. Coronary flow reserve was unchanged at 3.8 +/- 0.9 at baseline and after intracoronary diltiazem. Thus, treatment with diltiazem does not invalidate the measurement of coronary flow reserve for diagnostic purposes. Furthermore, these results suggest that attenuation of maximal coronary dilation by diltiazem is not a mechanism responsible for its antianginal effects.


This article has been cited by other articles:


Home page
Eur. J. Cardiothorac. Surg.Home page
M. Lemma, A. Innorta, M. Pettinari, A. Mangini, G. Gelpi, M. Piccaluga, P. Danna, and C. Antona
Flow dynamics and wall shear stress in the left internal thoracic artery: composite arterial graft versus single graft.
Eur. J. Cardiothorac. Surg., April 1, 2006; 29(4): 473 - 478.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
W. A. Parham, A. Bouhasin, J. P. Ciaramita, S. Khoukaz, S. C. Herrmann, and M. J. Kern
Coronary Hyperemic Dose Responses of Intracoronary Sodium Nitroprusside
Circulation, March 16, 2004; 109(10): 1236 - 1243.
[Abstract] [Full Text] [PDF]


Home page
Eur. J. Cardiothorac. Surg.Home page
M. Lemma, A. Mangini, G. Gelpi, A. Innorta, P. Danna, F. Lavarra, E. Piccaluga, and C. Antona
Effects of heart rate on phasic Y-graft blood flow and flow reserve in patients with complete arterial myocardial revascularizaton: an intravascular Doppler catheter study
Eur. J. Cardiothorac. Surg., July 1, 2003; 24(1): 81 - 85.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
N. Spyrou, M. A. Khan, S. D. Rosen, R. Foale, D. W. Davies, F. Sogliani, R. D. L. Stanbridge, and P. G. Camici
Persistent but reversible coronary microvascular dysfunction after bypass grafting
Am J Physiol Heart Circ Physiol, December 1, 2000; 279(6): H2634 - H2640.
[Abstract] [Full Text] [PDF]